CSL Limited (CSLLY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CSL Limited (CSLLY) trades at $21.77 with AI Score 48/100 (Grade C). CSL Limited is a global biotechnology leader specializing in plasma-derived therapies and influenza vaccines. Market cap: $84.30B, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for CSLLY: CSLLY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CSLLY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CSLLY: the 1 perspectives are evenly split.
How is this calculated? →CSL Limited (CSLLY) Healthcare & Pipeline Overview
CSL Limited, a global biotechnology company, develops and manufactures plasma-derived therapies and influenza vaccines. Operating through CSL Behring and Seqirus, the company addresses critical needs in immunology, hematology, and influenza prevention. With a strong market capitalization and dividend yield, CSL Limited maintains a robust presence in the global biopharmaceutical landscape.
What Is the Investment Thesis for CSLLY?
CSL Limited presents a compelling investment case driven by its leadership in plasma-derived therapies and influenza vaccines. With a market capitalization of $84.30B and a P/E ratio of 24.1, the company demonstrates financial stability and growth potential. A dividend yield of 3.04% offers investors a steady income stream. Key growth catalysts include expanding its plasma collection network and developing innovative therapies. However, potential risks include regulatory challenges and competition from biosimilars. The company's strong profit margin of 9.2% and gross margin of 48.6% underscore its operational efficiency and pricing power. CSL's beta of 0.21 indicates lower volatility compared to the market, making it a relatively stable investment.
Based on FMP financials and quantitative analysis
CSLLY Key Highlights
- Market capitalization of $84.30B reflects CSL Limited's significant presence in the biotechnology industry.
- P/E ratio of 24.1 indicates investor confidence in the company's earnings potential.
- Profit margin of 9.2% demonstrates CSL Limited's ability to generate profits from its operations.
- Gross margin of 48.6% highlights the company's efficient cost management and pricing strategy.
- Dividend yield of 3.04% provides investors with a consistent income stream.
Who Are CSLLY's Competitors?
CSLLY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ARGNF argenx SE | $803.19 | -10.76% | $49.70B | 49 |
| CHGCF Chugai Pharmaceutical Co., Ltd. | $46.51 | +0.93% | $76.54B | 55 |
| CHGCY Chugai Pharmaceutical Co., Ltd. | $23.26 | -0.47% | $76.56B | 55 |
| GLAXF GSK plc | $25.30 | -1.82% | $101.34B | 58 |
| GNMSF Genmab A/S | $273.50 | -0.55% | $16.79B | 55 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CSLLY's Key Strengths?
- Global leader in plasma-derived therapies.
- Strong research and development capabilities.
- Diverse product portfolio.
- Established global distribution network.
What Are CSLLY's Weaknesses?
- Reliance on plasma supply.
- Exposure to regulatory risks.
- Competition from biosimilars.
- Currency exchange rate fluctuations.
What Could Drive CSLLY Stock Higher?
- Expansion of plasma collection network to secure a stable supply of plasma for manufacturing plasma-derived therapies.
- Investment in research and development to create innovative therapies for unmet medical needs.
- Geographic expansion into emerging markets to tap into new customer bases and revenue streams.
- Potential strategic acquisitions to expand product portfolio and market reach.
- Enhancement of influenza vaccine portfolio through Seqirus segment to capture a larger share of the market.
What Are the Key Risks for CSLLY?
- Changes in healthcare regulations could impact CSL Limited's ability to market and sell its products.
- Competition from other biotechnology companies could erode CSL Limited's market share.
- Supply chain disruptions could impact CSL Limited's ability to manufacture and distribute its products.
- Economic downturns could reduce demand for CSL Limited's products.
- Reliance on plasma supply exposes CSL to potential shortages and price fluctuations.
What Are the Growth Opportunities for CSLLY?
- Expansion of Plasma Collection Network: CSL Limited can drive growth by expanding its plasma collection network globally. Plasma-derived therapies are in high demand, and securing a stable supply of plasma is crucial. Investing in new collection centers and improving donor recruitment strategies will enhance CSL's production capacity and market share. The global plasma fractionation market is projected to reach $46.8 billion by 2027, presenting a significant opportunity for CSL to capitalize on this growing demand.
- Development of Innovative Therapies: CSL Limited's growth can be fueled by investing in research and development to create innovative therapies for unmet medical needs. Focusing on areas such as immunology, hematology, and neurology, CSL can develop novel treatments that address critical health challenges. The biopharmaceutical market is driven by innovation, and CSL's ability to bring new products to market will be a key factor in its long-term success. This is an ongoing opportunity.
- Geographic Expansion: CSL Limited can expand its presence in emerging markets to drive growth. Countries with growing healthcare systems and increasing access to medical treatments offer significant potential for CSL's products. By establishing partnerships, distribution networks, and manufacturing facilities in these regions, CSL can tap into new customer bases and revenue streams. This is an ongoing opportunity.
- Strategic Acquisitions: CSL Limited can pursue strategic acquisitions to expand its product portfolio and market reach. Acquiring companies with complementary technologies or therapies can enhance CSL's competitive position and accelerate its growth. Identifying and integrating synergistic businesses will be crucial for CSL's long-term success. The biopharmaceutical industry is characterized by consolidation, and CSL's ability to execute successful acquisitions will be a key driver of its growth. This is an ongoing opportunity.
- Enhancing Influenza Vaccine Portfolio: CSL Limited, through its Seqirus segment, can further enhance its influenza vaccine portfolio. Investing in research and development to create more effective and broadly protective influenza vaccines will be crucial. The global influenza vaccine market is projected to grow, driven by increasing awareness of the importance of vaccination and the ongoing threat of pandemic influenza. By developing innovative vaccines, CSL can capture a larger share of this market and improve public health outcomes. This is an ongoing opportunity.
What Opportunities Does CSLLY Have?
- Expansion into emerging markets.
- Development of innovative therapies.
- Strategic acquisitions.
- Increasing demand for plasma-derived therapies.
What Threats Does CSLLY Face?
- Changes in healthcare regulations.
- Competition from other biotechnology companies.
- Supply chain disruptions.
- Economic downturns.
What Are CSLLY's Competitive Advantages?
- Proprietary plasma fractionation technology.
- Strong brand reputation and customer loyalty.
- Extensive global distribution network.
- Significant investment in research and development.
- Stringent regulatory approvals and high barriers to entry.
What Does CSLLY Do?
Founded in 1916 in Melbourne, Australia, CSL Limited has evolved from a Commonwealth Serum Laboratories, a government organization focused on supplying vaccines to meet Australia's public health needs, into a global biotechnology leader. Today, CSL operates through two primary segments: CSL Behring and Seqirus. CSL Behring focuses on plasma-derived therapies, offering a range of products to treat immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also invests heavily in research and development of both plasma and non-plasma therapies. Seqirus, the second segment, manufactures and distributes non-plasma biotherapeutic products, with a primary focus on influenza vaccines. Seqirus is one of the world's largest influenza vaccine companies, dedicated to preventing seasonal and pandemic influenza. CSL's global reach extends to Australia, the United States, Germany, the United Kingdom, Switzerland, and China, among other countries. The company's commitment to innovation and patient care has solidified its position as a key player in the biopharmaceutical industry.
What Products and Services Does CSLLY Offer?
- Researches and develops biopharmaceutical products.
- Manufactures plasma-derived therapies for various medical conditions.
- Markets and distributes its products globally.
- Offers treatments for immunodeficiency disorders.
- Provides therapies for bleeding disorders.
- Develops and distributes influenza vaccines.
- Conducts research on plasma and non-plasma therapies.
How Does CSLLY Make Money?
- Develops and manufactures plasma-derived therapies and influenza vaccines.
- Sells its products to healthcare providers and patients through a global distribution network.
- Invests in research and development to create new and innovative therapies.
- Generates revenue through product sales, licensing agreements, and royalties.
What Industry Does CSLLY Operate In?
CSL Limited operates within the biotechnology industry, a sector characterized by rapid innovation, stringent regulatory oversight, and high growth potential. The global biotechnology market is projected to reach trillions of dollars by 2026, driven by advancements in genomics, personalized medicine, and biopharmaceutical development. CSL competes with other major players such as ARGNF (Argenx SE), CHGCF (Chugai Pharmaceutical), CHGCY (Chugai Pharmaceutical), GLAXF (GlaxoSmithKline), and GNMSF (Genmab A/S). These companies vie for market share in plasma-derived therapies and vaccine development. The industry is also influenced by factors such as aging populations, increasing healthcare expenditure, and the growing prevalence of chronic diseases.
Who Are CSLLY's Key Customers?
- Patients with immunodeficiency disorders.
- Individuals with bleeding disorders.
- People at risk of contracting influenza.
- Healthcare providers and hospitals.
- Government health agencies.
CSL Limited (CSLLY) Valuation Context
Valued at $84.30B, CSLLY is classified as a large-cap stock. Relative to its peer group, CSLLY's quantitative score of 48/100 is roughly in line with the peer average of 54/100.
CSLLY Revenue & Earnings Trend
In Q4 2025, CSLLY generated $8.30B in top-line revenue, marking a sequential increase of 14.4%. The company recorded net income of $401.7M, with diluted EPS of $0.05. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare.
Company Profile
CSL Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Melbourne, AU. The company is led by CEO Gordon Naylor DipCompSc. CSLLY has traded publicly since 2009.
ROE 8%Key Financial Metrics
Return on equity for CSL Limited stands at 7.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.8%, showing how much profit it generates from its asset base. CSLLY trades at a trailing price-to-earnings ratio of 24.09, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 9.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.57 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.2%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 6/9Financial Health
CSL Limited's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 5.11 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project CSL Limited revenue of about $16.28B for fiscal 2026, with EPS near $1.57. The estimate reflects 8 contributing analysts.
CSLLY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in CSL's long-term growth potential, indicating that executives believe the company is undervalued.
- Community sentiment has leaned positive, with discussions highlighting CSL's strong position in the biopharmaceutical sector and increasing demand for its products.
- Market perception has improved following recent announcements of successful product launches, reinforcing the company's innovation capabilities.
- Investors are optimistic about CSL's strategic partnerships, which could enhance its market reach and drive future revenue growth.
Bear Case
- There are concerns about regulatory challenges facing CSL, which could impact its ability to bring new products to market in a timely manner.
- Recent social sentiment has shown some skepticism regarding the sustainability of CSL's growth, with discussions around potential competition in the industry.
- Some investors are worried about macroeconomic factors that could affect CSL's supply chain and operational costs, leading to uncertainty in profitability.
- Bearish views have emerged from analysts citing potential overvaluation based on past performance, suggesting a correction might be due.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $8.30B | $402M | $0.05 |
| Q2 2025 | $7.26B | $1.03B | — |
| Q4 2024 | $8.21B | $2.01B | $0.26 |
| Q2 2024 | $6.75B | $741M | $0.14 |
Based on FMP financials and quantitative analysis
CSLLY Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
CSLLY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CSLLY.
Price Targets
Wall Street price target analysis for CSLLY.
CSLLY MoonshotScore
What does this score mean?
The MoonshotScore rates CSLLY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Gordon Naylor DipCompSc
CEO
Gordon Naylor holds a Diploma in Computer Science. He has been with CSL Limited for several years, holding various leadership positions before becoming the CEO. His experience spans across different aspects of the company's operations, including manufacturing, supply chain, and commercial strategy. He is known for his focus on innovation and operational excellence, driving CSL's growth and expansion in the global biopharmaceutical market.
Track Record: Under Gordon Naylor's leadership, CSL Limited has continued to expand its global presence and strengthen its position as a leader in plasma-derived therapies and influenza vaccines. He has overseen the launch of several new products and the expansion of the company's plasma collection network. His strategic decisions have contributed to CSL's strong financial performance and its commitment to innovation.
CSL Limited ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. CSLLY functions as a Level 1 ADR, meaning it trades over-the-counter (OTC) without needing to meet the strict listing requirements of exchanges like the NYSE or NASDAQ. This allows U.S. investors to invest in CSL Limited more easily.
- Home Market Ticker: Australian Securities Exchange (ASX), Australia
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: CSLL
CSLLY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that CSL Limited (CSLLY) has chosen not to meet the minimum financial and disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier may have limited or no reporting requirements, which can make it difficult for investors to obtain reliable information about their financial performance and operations. Investing in OTC Other stocks carries a higher degree of risk compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low trading volume and liquidity.
- Higher price volatility.
- Potential for fraud and manipulation.
- Lack of regulatory oversight.
- Verify the company's registration and legal status.
- Obtain and review available financial statements.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any regulatory actions or legal proceedings.
- Long operating history (founded in 1916).
- Global presence and operations.
- Established product portfolio and market position.
- Presence in the Biotechnology sector.
- Operates through CSL Behring and Seqirus segments.
What Investors Ask About CSL Limited (CSLLY) — Healthcare
What does CSL Limited do?
CSL Limited is a global biotechnology company that develops, manufactures, and markets plasma-derived therapies and influenza vaccines. Through its CSL Behring segment, the company offers treatments for immunodeficiency, bleeding disorders, and neurological disorders. The Seqirus segment focuses on influenza vaccines, providing protection against seasonal and pandemic influenza. CSL's products are used by healthcare providers and patients worldwide to treat and prevent life-threatening conditions.
What do analysts say about CSLLY stock?
Analyst consensus on CSLLY stock reflects a generally positive outlook, driven by the company's strong market position and growth prospects. Key valuation metrics, such as the P/E ratio and dividend yield, are closely monitored. Growth considerations include the expansion of the plasma collection network, development of innovative therapies, and geographic expansion. However, analysts also consider potential risks, such as regulatory challenges and competition from biosimilars. The overall sentiment suggests that CSLLY is a stable investment with long-term growth potential.
What are the main risks for CSLLY?
The main risks for CSLLY include regulatory challenges, competition from biosimilars, and reliance on plasma supply. Changes in healthcare regulations could impact the company's ability to market and sell its products. Competition from biosimilars could erode CSL's market share and pricing power. The company's reliance on plasma supply exposes it to potential shortages and price fluctuations. Additionally, economic downturns and supply chain disruptions could negatively impact CSL's financial performance.
What are the key factors to evaluate for CSLLY?
CSL Limited (CSLLY) holds an AI score of 48/100 (low). P/E: 24.1x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does CSLLY data refresh on this page?
CSLLY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CSLLY's recent stock price performance?
CSL Limited (CSLLY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Global leader in plasma-derived therapies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CSLLY overvalued or undervalued right now?
CSL Limited (CSLLY) trades at 24.1x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CSLLY?
Before investing in CSL Limited (CSLLY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide additional insights.